• Skip to main content
  • Skip to header right navigation
  • Skip to site footer

Log in
  • Search
    • Search All SAGES Content
    • Search SAGES Guidelines
    • Search the Video Library
    • Search the Image Library
    • Search the Abstracts Archive
www.sages.org

SAGES

Reimagining surgical care for a healthier world

  • Home
    • Search
    • SAGES Home
    • SAGES Foundation Home
  • About
    • Awards
    • Who Is SAGES?
    • Leadership
    • Our Mission
    • Advocacy
    • Committees
      • SAGES Board of Governors
      • Officers and Representatives of the Society
      • Committee Chairs and Co-Chairs
      • Committee Rosters
      • SAGES Past Presidents
  • Meetings
    • SAGES NBT Innovation Weekend
    • SAGES Annual Meeting
      • 2026 Scientific Session Call for Abstracts
      • 2026 Emerging Technology Call for Abstracts
    • CME Claim Form
    • SAGES Past, Present, Future, and Related Meeting Information
    • SAGES Related Meetings & Events Calendar
  • Join SAGES!
    • Membership Application
    • Membership Benefits
    • Membership Types
      • Requirements and Applications for Active Membership in SAGES
      • Requirements and Applications for Affiliate Membership in SAGES
      • Requirements and Applications for Associate Active Membership in SAGES
      • Requirements and Applications for Candidate Membership in SAGES
      • Requirements and Applications for International Membership in SAGES
      • Requirements for Medical Student Membership
    • Member Spotlight
    • Give the Gift of SAGES Membership
  • Patients
    • Join the SAGES Patient Partner Network (PPN)
    • Patient Information Brochures
    • Healthy Sooner – Patient Information for Minimally Invasive Surgery
    • Choosing Wisely – An Initiative of the ABIM Foundation
    • All in the Recovery: Colorectal Cancer Alliance
    • Find A SAGES Surgeon
  • Publications
    • Clinical / Practice / Training Guidelines, Statements, and Standards of Practice
    • Sustainability in Surgical Practice
    • SAGES Stories Podcast
    • Patient Information Brochures
    • Patient Information From SAGES
    • TAVAC – Technology and Value Assessments
    • Surgical Endoscopy and Other Journal Information
    • SAGES Manuals
    • MesSAGES – The SAGES Newsletter
    • COVID-19 Archive
    • Troubleshooting Guides
  • Education
    • Wellness Resources – You Are Not Alone
    • Avoid Opiates After Surgery
    • SAGES Subscription Catalog
    • SAGES TV: Home of SAGES Surgical Videos
    • The SAGES Safe Cholecystectomy Program
    • Masters Program
    • Resident and Fellow Opportunities
      • MIS Fellows Course
      • SAGES Robotics Residents and Fellows Courses
      • SAGES Free Resident Webinar Series
      • Fluorescence-Guided Surgery Course for Fellows
      • Fellows’ Career Development Course
    • SAGES S.M.A.R.T. Enhanced Recovery Program
    • SAGES @ Cine-Med Products
      • SAGES Top 21 Minimally Invasive Procedures Every Practicing Surgeon Should Know
      • SAGES Pearls Step-by-Step
      • SAGES Flexible Endoscopy 101
    • SAGES OR SAFETY Video Activity
  • Opportunities
    • Fellowship Recognition Opportunities
    • SAGES Advanced Flexible Endoscopy Area of Concentrated Training (ACT) SEAL
    • Multi-Society Foregut Fellowship Certification
    • Research Opportunities
    • FLS
    • FES
    • FUSE
    • Jobs Board
    • SAGES Go Global: Global Affairs and Humanitarian Efforts
  • OWLS/FLS
You are here: Home / Abstracts / No IV, No Problem: Intraosseous Administration of Tranexamic Acid is as Effective as Intravenous in a Porcine Hemorrhage Model

No IV, No Problem: Intraosseous Administration of Tranexamic Acid is as Effective as Intravenous in a Porcine Hemorrhage Model

Michael Lallemand, MD, Donald Moe, MD, John McClellan, Mike Loughren, PhD, Shannon Marko, DVM, Matthew Eckert, MD, Matthew Martin, MD. Madigan Army Medical Center

Objectives: The acute coagulopathy of trauma after massive hemorrhage is often accompanied by hyperfibrinolysis. Tranexamic acid (TXA) is capable of reversing this physiologic phenomenon and when given early decreases mortality from bleeding. The maximum effect on mortality is seen if given within one hour post-injury and there is potential harm if given beyond three hours from injury. Establishing IV access can be difficult in a tactical setting and intraosseous (IO) access is the preferred route of drug administration. To date there is no data on the relative efficacy of TXA administered by the IO route. We hypothesize intraosseous TXA will reverse hyperfibrinolysis similarly to IV TXA.

Methods: Using a porcine traumatic hemorrhage + ischemia-reperfusion (IR) model 16 swine underwent hemorrhagic shock followed by tissue plasminogen activator (tPA) infusion to induce hyperfibrinolysis, which was confirmed with Rotational Thromboelastometry (ROTEM). Animals were randomized to receive an IV or tibial IO TXA infusion over 10 minutes. Blood samples were analyzed using ROTEM to monitor reversal of hyperfibrinolysis. Serum samples were collected for analysis of drug concentrations.

Results: After hemorrhage and IR injury the IV and IO groups had similar physiologic derangements in MAP (48 vs 49.5), lactate (11.1 vs 10.8), and pH (7.20 vs 7.22), with all p-values being not-significant. Intraosseous administration of TXA showed a correction of the lysis index at 30 minutes to 100 in the extrinsic pathway and 98.3 in the intrinsic pathways, compared to 99.8 and 98.4 in the IV group (p=0.18, p=0.44). Peak serum levels of TXA after IV and IO administration show concentrations of 160.9µg/mL and 132.57µg/mL respectively (p=0.053). Peak levels occurred at 10 minutes after the start of the infusion (completion of infusion) in both groups. Drug levels were tracked for four hours after the start of the infusion. At the end of this monitoring phase the plasma concentrations of IV and IO administered TXA were equivalent at 20.59µg/mL and 23.53µg/mL respectively (p = 0.25). Both groups showed similar rates of dynamic clearance of the drug.

Conclusions: Intraosseous administration of TXA is equally as effective as intravenous administration in reversing hyperfibrinolysis in a porcine model of hemorrhagic shock. Intraosseous administration was associated with a slightly lower peak level versus IV, but otherwise similar serum TXA levels, pharmacokinetics, and clearance.


Presented at the SAGES 2017 Annual Meeting in Houston, TX.

Abstract ID: 79681

Program Number: MSS16

Presentation Session: Full-Day Military Surgical Symposium – Trauma/Critical Care Presentations

Presentation Type: MSSPodium

132

Share this:

  • Click to share on X (Opens in new window) X
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Mastodon (Opens in new window) Mastodon
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on Bluesky (Opens in new window) Bluesky

Related


sages_adbutler_leaderboard

Hours & Info

11300 West Olympic Blvd, Suite 600
Los Angeles, CA 90064

1-310-437-0544

[email protected]

Monday – Friday
8am to 5pm Pacific Time

Find Us Around the Web!

  • Bluesky
  • X
  • Instagram
  • Facebook
  • YouTube

Copyright © 2025 · SAGES · All Rights Reserved

Important Links

Healthy Sooner: Patient Information

SAGES Guidelines, Statements, & Standards of Practice

SAGES Manuals